Get the Stockscreener App
4.34
3.77%
-0.17
Pre-market:
4.33
-0.010
-0.23%
Precigen Inc stock is traded at $4.34, with a volume of 5.54M.
It is down -3.77% in the last 24 hours and up +5.34% over the past month.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
See More
Previous Close:
$4.51
Open:
$4.49
24h Volume:
5.54M
Relative Volume:
1.29
Market Cap:
$1.55B
Revenue:
$9.68M
Net Income/Loss:
$-250.64M
P/E Ratio:
-3.1004
EPS:
-1.3998
Net Cash Flow:
$-89.83M
1W Performance:
+2.36%
1M Performance:
+5.34%
6M Performance:
+13.32%
1Y Performance:
+212.23%
1-Day Range:
$4.33
$4.58
1-Week Range:
$4.11
$4.6795
52-Week Range:
$1.28
$5.465
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.34 | 1.61B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Promising Long-Term Data for Precigen (PGEN) in RRP Treatment - GuruFocus
Precigen Q1 earnings call highlights - MSN
Precigen jumps after Q1 beat as Papzimeos launch momentum takes hold - MSN
Number of shareholders of Precigen, Inc. – NASDAQ:PGEN - TradingView
Number of shareholders of Precigen Inc – BX:I5X - TradingView
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years - PR Newswire
Precigen (PGEN) price target increased by 11.76% to 9.69 - MSN
PGEN Stock Price, Quote & Chart | PRECIGEN INC (NASDAQ:PGEN) - ChartMill
Precigen (PGEN) Maintained by HC Wainwright & Co. -- Price Targe - GuruFocus
Precigen (PGEN) CFO gains 87,500 shares from RSU vesting - Stock Titan
PRECIGEN (PGEN) CCO Phil Tennant acquires 62,500 shares through RSU vesting - Stock Titan
Precigen (PGEN) CLO converts 62,500 RSUs into common shares - Stock Titan
Precigen’s PAPZIMEOS Receives FDA Orphan Drug Exclusivity for RRP Treatment, Blocking Similar Drugs for Seven Years - geneonline.com
FDA grants orphan drug exclusivity for Precigen’s PAPZIMEOS - Investing.com UK
Precigen (PGEN) Secures Orphan Drug Status for Papzimeos Treatme - GuruFocus
FDA grants orphan drug exclusivity for Precigen’s PAPZIMEOS By Investing.com - Investing.com Australia
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States - PR Newswire
Spotlight On 3 Growth Companies With Strong Insider Stakes - simplywall.st
Precigen CEO set for J.P. Morgan and Goldman Sachs healthcare fireside chats - Stock Titan
Precigen’s lead cancer therapy is fueling a massive stock rally — here’s what Wall Street sees next - MSN
What Precigen (PGEN)'s PAPZIMEOS-Fueled Q1 Revenue Surge Means For Shareholders - simplywall.st
Precigen (PGEN): The Best Penny Stock to Buy for Long Term - Insider Monkey
Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade) (NASDAQ:PGEN) - Seeking Alpha
5 Best Penny Stocks to Buy for Long Term - Insider Monkey
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript - Intellectia AI
PGEN - Intellectia AI
Precigen’s PAPZIMEOS Launch Drives Surging Q1 Revenue - TipRanks
How Surging PAPZIMEOS Revenue And Narrower Losses At Precigen (PGEN) Have Changed Its Investment Story - Sahm
Equities Analysts Set Expectations for Precigen Q3 Earnings - MarketBeat
Precigen Q1 earnings preview - MSN
Earnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Point72 (PGEN) reports 6.74M shares, 1.9% stake as of Mar 31, 2026 - Stock Titan
Precigen, Inc. (NASDAQ:PGEN) Q1 2026 Earnings Call Transcript - Insider Monkey
Precigen (PGEN) Shares Surge After Strong Q1 2026 Earnings Repor - GuruFocus
Precigen (PGEN) Reports Strong Q1 Earnings, Shares Surge Nearly 18% - GuruFocus
Earnings call transcript: Precigen beats Q1 2026 forecasts, stock surges - Investing.com UK
Earnings call transcript: Precigen beats Q1 2026 forecasts, stock surges By Investing.com - Investing.com Australia
Precigen Earnings Call Highlights PAPZIMEOS Launch Surge - TipRanks
PGEN Rated Buy by HC Wainwright & Co. -- Price Target Raised to $11.00 - GuruFocus
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):